Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240383 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study With LT, Monotherapy, PPAR
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,260
- Enrollment target
NCT00240383 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,260 participants.
The verdict
NCT00240383, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240383
The ClinicalTrials.gov registry entry for NCT00240383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00240383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240383 about?
NCT00240383 is a clinical study titled "Dose Ranging Study With LT, Monotherapy, PPAR". A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
What is the current status of trial NCT00240383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,260 participants. The study started on 2002-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00240383?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00240383?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.